Tachimori, Hisateru



School of Medicine, Endowed Course for Health system Innovation (Shinanomachi)


Project Professor (Non-tenured)


Books 【 Display / hide

  • Service use

    Evans-Lacko S., Tachimori H., Kovess-Masféty V., Chatterji S., Thornicroft G., Mental Disorders Around the World: Facts and Figures from the WHO World Mental Health Surveys, 2018.01

Papers 【 Display / hide

  • Consultation-liaison psychiatry in Japan: a nationwide retrospective observational study

    Shinjo D., Tachimori H., Maruyama-Sakurai K., Fujimori K., Inoue N., Fushimi K.

    BMC Psychiatry (BMC Psychiatry)  21 ( 1 )  2021.12

     View Summary

    Background: Consultation-liaison psychiatry (CLP)—professional psychiatric care provided to coordinate with surgical or medical treatment of inpatients with psychiatric disorders—was included in universal health coverage in Japan in 2012. Despite evidence of benefits of CLP, basic data and geographic distribution information regarding CLP at the national level remain unclear. This study aimed to 1) identify the geographic disparity of CLP in Japan and 2) investigate the association between number of consultations per CLP patient and region. Methods: We retrospectively analyzed anonymized data retrieved from the Japanese administrative inpatient database regarding inpatients who were provided CLP between April 2012 and March 2017. Demographic characteristics were summarized and geographic disparity by prefecture was visualized for fiscal years 2012 and 2016; we also summarized the data according to region. Multivariate linear regression analysis was used to investigate association between the number of consultations per CLP patient and region after adjusting for covariates. Results: Data from a total of 46,171 patients who received 138,866 CLP services were included. Results revealed more patients aged 75–84 years received CLPs than any other age group (29.7%) and the overall male/female ratio was 53:47 in 2016. In 2012 and 2016, 24.2 and 30.7% of CLP patients, respectively, were transferred to other hospitals; 9.7 and 8.8%, respectively, discharged due to the death. CLP services were provided in 14 prefectures in 2012 and 33 by 2016; 14 prefectures had no available CLP services. After adjusting for covariates, Tohoku (β = − 0.220, p < 0.034), Chugoku (β = − 0.160, p < 0.026), and Shikoku (β = − 0.555, p < 0.001) had a significant negative correlation with the number of consultations per CLP patient compared with Hokkaido region (an adjusted R square (R2) = 0.274). Conclusions: Our study clarified the characteristics of patients in Japan who received CLPs and the geographic disparity in CLP services. Although 5 years had passed since CLP was introduced, the results imply wide availability of CLP nationally. The analysis data provided may inform future policies to improve CLP services.

  • Risk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder

    Ishizuya A., Enomoto M., Tachimori H., Takahashi H., Sugihara G., Kitamura S., Mishima K.

    Scientific Reports (Scientific Reports)  11 ( 1 )  2021.12

     View Summary

    Poor adherence is a major concern in the treatment of attention-deficit/hyperactivity disorder (ADHD). The objective of this study was to evaluate factors linked to early interruption of and low adherence to treatment with osmotic-release oral system methylphenidate hydrochloride (OROS-MPH) in pediatric patients with ADHD. A total of 1353 young people (age 6–17 years) with a diagnosis of ADHD who newly started OROS-MPH were extracted from the pharmacoepidemiological data of 3 million people in Japan. The cohort was retrospectively surveyed every month for 12 months. Ten possible risk factors were extracted from the data and analyzed by multivariable logistic regression. Sensitivity analysis was conducted to ensure the robustness of the analysis. The results revealed that treatment adherence was generally poor, with a tendency for discontinuation in the early stage. Multivariable logistic regression results showed that adherence is reduced by female sex, lower starting dose, and concomitant atomoxetine or hypnotics. These findings may help clinicians to predict the risk of poor adherence in the early stage of treatment and improve not only patients’ symptoms, but also their quality of life.

  • Perilla oil and bifidobacterium for alleviating fear of cancer recurrence in breast cancer survivors: Study protocol for a three-arm phase II randomized controlled study (pob study)

    Sasaki Y., Honyashiki M., Kinoshita T., Matsui A., Nakashoji A., Inagawa T., Ikezawa S., Yoshimura N., Yamamura R., Amano M., Tomo Y., Tachimori H., Matsuoka Y.J., Okubo R.

    Methods and Protocols (Methods and Protocols)  4 ( 3 )  2021.09

     View Summary

    The fear of cancer recurrence (FCR) is the most common and most severe unmet need among cancer survivors. Safe treatments for the FCR that are easily disseminated are greatly needed. Our primary aim is a preliminary evaluation of the efficacy and effect size of perilla oil, which is rich in omega-3 fatty acids, and Bifidobacterium, a probiotic, on FCR in breast cancer survivors after the completion of chemotherapy. This study has been planned as an exploratory clinical study (phase II) and will be conducted as a three-arm, 12-week parallel group, masked-rater randomized controlled trial. Fifteen participants will be randomized with 1:1:1 allocation to receive Bifidobacterium plus perilla oil, Bifidobacterium alone, or no intervention (control). Interventions will end within 12 weeks after the random allocation of each participant. The participants will be outpatients with invasive breast cancer aged 20 years or older whose chemotherapy was completed at least 6 months before registration; hormone therapy may be ongoing. The primary outcome will be severity of FCR at 12 weeks assessed by masked raters using the 4-item Concerns about Recurrence Scale concerning overall fear of recurrence. The study protocol for the current study is registered in the Japan Registry of Clinical Trials (jRCTs031200029).

  • Hospital admission for type 2 diabetes mellitus under the Universal Coverage Scheme in Thailand: A time- And geographical-trend analysis, 2009-2016

    Laowahutanon T., Nakamura H., Tachimori H., Nomura S., Liabsuetrakul T., Lim A., Rawdaree P., Suchonwanich N., Yamamoto H., Ishizuka A., Shibuya K., Miyata H., Chongsuvivatwong V.

    PLoS ONE (PLoS ONE)  16 ( 7 July )  2021.07

     View Summary

    Background Descriptive analyses of 2009-2016 were performed using the data of the Universal Coverage Scheme (UCS) which covers nearly 70 percent of the Thai population. The analyses described the time and geographical trends of nationwide admission rates of type 2 diabetes mellitus (T2DM) and its complications, including chronic kidney disease (CKD), myocardial infarction, cerebrovascular diseases, retinopathy, cataract, and diabetic foot amputation. Methods and findings The database of T2DM patients aged 15-100 years who were admitted between 2009 and 2016 under the UCS and that of the UCS population were retrieved for the analyses. The admitted cases of T2DM were extracted from the database using disease codes of principal and secondary diagnoses defined by the International Classification of Diseases 9th and 10th Revisions. The T2DM admission rates in 2009-2016 were the number of admissions divided by the number of the UCS population. The standardized admission rates (SARs) were further estimated in contrast to the expected number of admissions considering age and sex composition of the UCS population in each region. A linearly increased trend was found in T2DM admission rates from 2009 to 2016. Female admission rates were persistently higher than that of males. In 2016, an increase in the T2DM admission rates was observed among the older ages relative to that in 2009. Although the SARs of T2DM were generally higher in Bangkok and central regions in 2009, except that with CKD and foot amputation which had higher trends in northeastern regions, the geographical inequalities were fairly reduced by 2016. Conclusion Admission rates of T2DM and its major complications increased in Thailand from 2009 to 2016. Although the overall geographical inequalities in the SARs of T2DM were reduced in the country, further efforts are required to improve the health system and policies focusing on risk factors and regions to manage the increasing T2DM.

  • Resilience building for mood disorders: Theoretical introduction and the achievements of the Re-Work program in Japan

    Arima H., Akiyama T., de Moura P.A., Bernick P., Sakai Y., Ozaki Y., Matsumoto S., Ohki Y., Igarashi Y., Tachimori H., Yamaguchi S.

    Asian Journal of Psychiatry (Asian Journal of Psychiatry)  58 2021.04

    ISSN  18762018

     View Summary

    Mood disorders are common, tend to recur, cause sickness absence, and lead to economic loss. Since past experiences of mood disorder episodes often increase future vulnerability, it is imperative to assist those mood disorder patients who want to resume working to build resilience to prevent relapse. Paralleling efforts in the West, a resilience-building program utilizing the principles of the Illness Management and Recovery program was first developed in Japan in 1997. The purpose of this survey is to introduce the concept and theory behind the Re-Work program and to review studies that report on program assessment, content, effects and associated factors, and prognosis of participants. A literature search performed with PubMed and Igaku chuou zasshi (Ichushi) identified 30 relevant studies. One of these reported on a tool developed to assess readiness for returning to work. Concerning program content, a group therapy setting and cognitive behavioral therapy were found to be effective. Physical exercise and relaxation techniques may be useful as secondary program components. Several studies report on program effects, but there may be factors that limit these effects. The prognosis for relapse prevention after the resumption of work may be better for Re-Work program participants than for a control group. Further research in this area is needed to confirm program effectiveness and related factors.

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • Corrigendum to “The epidemiology of alcohol use disorders cross-nationally: Findings from the World Mental Health Surveys” [Addict. Behav. 102 (2020) 106128] (Addictive Behaviors (2020) 102, (S0306460319304897), (10.1016/j.addbeh.2019.106128))

    Glantz M.D., Bharat C., Degenhardt L., Sampson N.A., Scott K.M., Lim C.C.W., Al-Hamzawi A., Alonso J., Andrade L.H., Cardoso G., De Girolamo G., Gureje O., He Y., Hinkov H., Karam E.G., Karam G., Kovess-Masfety V., Lasebikan V., Lee S., Levinson D., McGrath J., Medina-Mora M.E., Mihaescu-Pintia C., Mneimneh Z., Moskalewicz J., Navarro-Mateu F., Posada-Villa J., Rapsey C., Stagnaro J.C., Tachimori H., Have M.T., Tintle N., Torres Y., Williams D.R., Ziv Y., Kessler R.C.

    Addictive Behaviors (Addictive Behaviors)  106 2020.07

    ISSN  03064603

     View Summary

    The authors regret that the abovementioned article published online September 16, 2019, had an error in the author affiliations. The edited author affiliations are shown above. The authors also regret that the names of the WHO World Mental Health Survey Collaborators were omitted from the end of the article. “The WHO World Mental Health Survey collaborators are Sergio Aguilar-Gaxiola, MD, PhD; Ali Al-Hamzawi, MD; Mohammed Salih Al-Kaisy, MD; Jordi Alonso, MD, PhD; Laura Helena Andrade, MD, PhD; Lukoye Atwoli, MD, PhD; Corina Benjet, PhD; Guilherme Borges, ScD; Evelyn J. Bromet, PhD; Ronny Bruffaerts, PhD; Brendan Bunting, PhD; Jose Miguel Caldas-de-Almeida, MD, PhD; Graça Cardoso, MD, PhD; Somnath Chatterji, MD; Alfredo H. Cia, MD; Louisa Degenhardt, PhD; Koen Demyttenaere, MD, PhD; Silvia Florescu, MD, PhD; Giovanni de Girolamo, MD; Oye Gureje, MD, DSc, FRCPsych; Josep Maria Haro, MD, PhD; Meredith Harris, PhD; Hristo Hinkov, MD, PhD; Chi-yi Hu, MD, PhD; Peter de Jonge, PhD; Aimee Nasser Karam, PhD; Elie G. Karam, MD; Norito Kawakami, MD, DMSc; Ronald C. Kessler, PhD; Andrzej Kiejna, MD, PhD; Viviane Kovess-Masfety, MD, PhD; Sing Lee, MB, BS; Jean-Pierre Lepine, MD; John McGrath, MD, PhD; Maria Elena Medina-Mora, PhD; Zeina Mneimneh, PhD; Jacek Moskalewicz, PhD; Fernando Navarro-Mateu, MD, PhD; Marina Piazza, MPH, ScD; Jose Posada-Villa, MD; Kate M. Scott, PhD; Tim Slade, PhD; Juan Carlos Stagnaro, MD, PhD; Dan J. Stein, FRCPC, PhD; Margreet ten Have, PhD; Yolanda Torres, MPH, Dra.HC; Maria Carmen Viana, MD, PhD; Daniel V. Vigo, MD, DrPH; Harvey Whiteford, MBBS, PhD; David R. Williams, MPH, PhD; and Bogdan Wojtyniak, ScD.” The authors would like to apologise for any inconvenience caused.